Paperpal Prime Logo

Antibodies : Impact Factor & More

eISSN: 2073-4468pISSN: 2073-4468
JournalOpen Access
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Antibodies

Antibodies Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher Multidisciplinary Digital Publishing Institute (MDPI)
Language English
Frequency Quarterly
Article Processing ChargesCHF 1600
Publication Time6
Editorial Review ProcessBlind peer review
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 6
Editorial Review Detail
Editorial TeamVisit website
Review ProcessBlind peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY
OA statementVisit website
View less

Planning to publish in Antibodies ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Antibodies

Sera of Healthy First-Degree Relatives of SLE Patients Contain Autoantibodies to Globular Domains of C1q
  • 20 Jul 2026
  • Antibodies
The Diagnostic and Clinical Significance of Anti-Mutated Citrullinated Vimentin Antibodies in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Scoping Review
  • 13 Jul 2026
  • Antibodies
Natural Versus Vaccine-Induced Immunity Against HPV: A Comparative Review of Antibody Response and Cancer Prevention
  • 13 Jul 2026
  • Antibodies
A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications
  • 10 Jul 2026
  • Antibodies
Beyond the Surface: Antinuclear Antibodies in Rheumatoid Arthritis\u2014Experiences from a Single-Center, Cross-Sectional Observational Study
  • 10 Jul 2026
  • Antibodies
Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss
  • 3 Jul 2026
  • Antibodies
Sera of Healthy First-Degree Relatives of SLE Patients Contain Autoantibodies to Globular Domains of C1q
  • 20 Jul 2026
  • Antibodies
The Diagnostic and Clinical Significance of Anti-Mutated Citrullinated Vimentin Antibodies in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Scoping Review
  • 13 Jul 2026
  • Antibodies
Natural Versus Vaccine-Induced Immunity Against HPV: A Comparative Review of Antibody Response and Cancer Prevention
  • 13 Jul 2026
  • Antibodies
A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications
  • 10 Jul 2026
  • Antibodies
Beyond the Surface: Antinuclear Antibodies in Rheumatoid Arthritis\u2014Experiences from a Single-Center, Cross-Sectional Observational Study
  • 10 Jul 2026
  • Antibodies
Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss
  • 3 Jul 2026
  • Antibodies

FAQs on Antibodies